Celsion Co. (NASDAQ:CLSN) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.84 and traded as high as $1.81. Celsion shares last traded at $1.79, with a volume of 1,500 shares trading hands.

CLSN has been the subject of a number of research analyst reports. ValuEngine cut Universal Electronics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 6th. Zacks Investment Research upgraded Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research note on Monday, July 8th. Finally, Oppenheimer set a $13.00 price objective on Alpine Immune Sciences and gave the company a “buy” rating in a research note on Tuesday, March 19th.

The business’s 50 day simple moving average is $1.84. The company has a market cap of $36.25 million, a price-to-earnings ratio of -2.68 and a beta of 1.93. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.22 and a current ratio of 4.22.

Celsion (NASDAQ:CLSN) last posted its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 65.35% and a negative net margin of 1,954.60%. As a group, equities research analysts expect that Celsion Co. will post -1.04 EPS for the current fiscal year.

An institutional investor recently raised its position in Celsion stock. BlackRock Inc. grew its holdings in Celsion Co. (NASDAQ:CLSN) by 21.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 142,426 shares of the biotechnology company’s stock after purchasing an additional 25,548 shares during the period. BlackRock Inc. owned about 0.76% of Celsion worth $202,000 as of its most recent SEC filing. Institutional investors own 4.76% of the company’s stock.

Celsion Company Profile (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Featured Article: Moving Average (MA)

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.